135 related articles for article (PubMed ID: 8401768)
1. The effects of single and repeated administration of MAO inhibitors on acoustic startle response in rats.
Zajaczkowski W; Górka Z
Pol J Pharmacol; 1993; 45(2):157-66. PubMed ID: 8401768
[TBL] [Abstract][Full Text] [Related]
2. Some central effects of brofaromine given repeatedly are phase-dependent.
Górka Z; Zajaczkowski W
Pol J Pharmacol Pharm; 1990; 42(4):313-20. PubMed ID: 2097592
[TBL] [Abstract][Full Text] [Related]
3. Light-dark phase differences in behavioral effects of moclobemide in rats.
Górka Z; Zajaczkowski W
Pol J Pharmacol Pharm; 1991; 43(3):177-86. PubMed ID: 1961692
[TBL] [Abstract][Full Text] [Related]
4. The effect of imipramine after single and repeated administration on the apomorphine response in the acoustic startle reflex in rats.
Zajaczkowski W; Górka Z
Pol J Pharmacol Pharm; 1992; 44(4):347-53. PubMed ID: 1363132
[TBL] [Abstract][Full Text] [Related]
5. Comparison of behavioral effects of moclobemide and deprenyl during forced swimming.
Ferigolo M; Barros HM; Marquardt AR; Tannhauser M
Pharmacol Biochem Behav; 1998 Jun; 60(2):431-7. PubMed ID: 9632226
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
Da Prada M; Keller HH; Kettler R
Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
[TBL] [Abstract][Full Text] [Related]
7. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
Lavian G; Finberg JP; Youdim MB
Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
[TBL] [Abstract][Full Text] [Related]
8. Effects of corticotropin-releasing factor on prepulse inhibition of the acoustic startle response in two rat strains.
Conti LH; Murry JD; Ruiz MA; Printz MP
Psychopharmacology (Berl); 2002 May; 161(3):296-303. PubMed ID: 12021833
[TBL] [Abstract][Full Text] [Related]
9. E2011 a novel, selective and reversible inhibitor of monoamine oxidase type A.
Kagaya T; Kajiwara A; Nagato S; Akasaka K; Kubota A
J Pharmacol Exp Ther; 1996 Jul; 278(1):243-51. PubMed ID: 8764357
[TBL] [Abstract][Full Text] [Related]
10. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo.
Colzi A; D'Agostini F; Cesura AM; Borroni E; Da Prada M
J Pharmacol Exp Ther; 1993 Apr; 265(1):103-11. PubMed ID: 8473998
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the effects of corticotropin-releasing factor on prepulse inhibition of the acoustic startle response in Brown Norway and Wistar-Kyoto rats.
Conti LH
Eur J Pharmacol; 2005 Jan; 507(1-3):125-34. PubMed ID: 15659302
[TBL] [Abstract][Full Text] [Related]
12. Effect of repeated treatment with high doses of selegiline on behaviour, striatal dopaminergic transmission and tyrosine hydroxylase mRNA levels.
Themann C; Alvarez Fischer D; Gross S; Westermann R; Weihe E; Kuschinsky K; Schäfer H; Ferger B
Naunyn Schmiedebergs Arch Pharmacol; 2002 Jan; 365(1):22-8. PubMed ID: 11862330
[TBL] [Abstract][Full Text] [Related]
13. The effect of various monoamine oxidase (MAO) inhibitors on the response of blood pressure of rats and cats to tyramine.
Abdo-Rubo A
Acta Physiol Hung; 1990; 75(4):321-36. PubMed ID: 2127505
[TBL] [Abstract][Full Text] [Related]
14. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression.
Weinstock M; Poltyrev T; Bejar C; Youdim MB
Psychopharmacology (Berl); 2002 Mar; 160(3):318-24. PubMed ID: 11889501
[TBL] [Abstract][Full Text] [Related]
15. Reversal of stress-induced deficit in aggression by monoamine oxidase inhibitors.
Ossowska G; Klenk-Majewska B; Danilczuk Z; Wróbel A; Zebrowska-Lupina I
Pol J Pharmacol; 1999; 51(5):391-7. PubMed ID: 10817539
[TBL] [Abstract][Full Text] [Related]
16. In vivo characterization of T-794, a novel reversible inhibitor of monoamine oxidase-A, as an antidepressant with a wide safety margin.
Kato M; Katayama T; Iwata H; Yamamura M; Matsuoka Y; Narita H
J Pharmacol Exp Ther; 1998 Mar; 284(3):983-90. PubMed ID: 9495858
[TBL] [Abstract][Full Text] [Related]
17. GABA and opioid mechanisms of the central amygdala underlie the withdrawal-potentiated startle from acute morphine.
Cabral A; Ruggiero RN; Nobre MJ; Brandão ML; Castilho VM
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):334-44. PubMed ID: 19150477
[TBL] [Abstract][Full Text] [Related]
18. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
19. The effects of monoamine oxidase inhibitors on the ejaculatory response induced by 5-methoxy-N,N-dimethyltryptamine in the rat.
Rényi L
Br J Pharmacol; 1986 Aug; 88(4):827-35. PubMed ID: 3091132
[TBL] [Abstract][Full Text] [Related]
20. Antidepressant-like effects of selegiline in the forced swim test.
Shimazu S; Minami A; Kusumoto H; Yoneda F
Eur Neuropsychopharmacol; 2005 Oct; 15(5):563-71. PubMed ID: 16139174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
